Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled multi-center phase III study to
evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer
(CRC) who have progressed on/after all approved drugs for CRC